645 Eli Lilly and Company $LLY Shares Purchased by Teamwork Financial Advisors LLC

Posted by Brian Himes on Oct 20th, 2026

Eli Lilly and Company logo Teamwork Financial Advisors LLC boosted its holdings in Eli Lilly and Company (NYSE:LLY – Free Report) by 6.0% during the 3rd quarter, according to its most recent disclosure with the SEC. The firm owned 11,307 shares of the company’s stock after buying an additional 645 shares during the period. Eli Lilly and Company makes up about 1.4% of Teamwork Financial Advisors LLC’s investment portfolio, making the stock its 25th largest position. Teamwork Financial Advisors LLC’s holdings in Eli Lilly and Company were worth $13,083,000 as of its most recent SEC filing.

Other hedge funds have also recently bought and sold shares of the company. Abel Hall LLC raised its holdings in shares of Eli Lilly and Company by 1.4% during the 3rd quarter. Abel Hall LLC now owns 2,713 shares of the company’s stock valued at $3,139,000 after buying an additional 38 shares during the period. James Hambro & Partners LLP lifted its position in Eli Lilly and Company by 38.3% during the 3rd quarter. James Hambro & Partners LLP now owns 1,831 shares of the company’s stock worth $2,123,000 after acquiring an additional 507 shares in the last quarter. Richards Merrill & Peterson Inc. boosted its holdings in Eli Lilly and Company by 8.6% in the 3rd quarter. Richards Merrill & Peterson Inc. now owns 1,255 shares of the company’s stock worth $1,452,000 after acquiring an additional 99 shares during the period. New Wave Wealth Advisors LLC boosted its holdings in Eli Lilly and Company by 3.5% in the 3rd quarter. New Wave Wealth Advisors LLC now owns 2,511 shares of the company’s stock worth $2,929,000 after acquiring an additional 84 shares during the period. Finally, Talbot Financial LLC boosted its holdings in Eli Lilly and Company by 0.3% in the 3rd quarter. Talbot Financial LLC now owns 37,225 shares of the company’s stock worth $43,072,000 after acquiring an additional 119 shares during the period. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Price Performance

Shares of LLY stock opened at $1,242.76 on Tuesday. The firm has a market cap of $1.17 trillion, a P/E ratio of 41.70, a P/E/G ratio of 1.67 and a beta of 0.46. The company has a debt-to-equity ratio of 1.41, a current ratio of 1.35 and a quick ratio of 1.00. Eli Lilly and Company has a 1-year low of $793.82 and a 1-year high of $1,292.65. The firm has a fifty day moving average of $1,180.34 and a two-hundred day moving average of $1,111.84.

Eli Lilly and Company (NYSE:LLY – Get Free Report) last released its earnings results on Wednesday, August 5th. The company reported $8.38 earnings per share for the quarter, topping the consensus estimate of $6.40 by $1.98. The company had revenue of $22.97 billion during the quarter, compared to the consensus estimate of $20.82 billion. Eli Lilly and Company had a net margin of 33.53% and a return on equity of 97.83%. The company’s revenue was up 47.7% on a year-over-year basis. During the same quarter in the previous year, the firm earned $6.31 EPS. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. As a group, research analysts anticipate that Eli Lilly and Company will post 33.56 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on LLY. Sanford C. Bernstein lifted their price objective on shares of Eli Lilly and Company from $1,300.00 to $1,385.00 and gave the company an “outperform” rating in a research note on Tuesday, July 14th. BMO Capital Markets reissued an “outperform” rating on shares of Eli Lilly and Company in a research report on Thursday, October 1st. Cantor Fitzgerald upped their target price on shares of Eli Lilly and Company from $1,410.00 to $1,440.00 and gave the company an “overweight” rating in a research note on Thursday, October 8th. Leerink Partners raised their price target on shares of Eli Lilly and Company from $1,119.00 to $1,232.00 and gave the company an “outperform” rating in a report on Thursday, June 25th. Finally, Wall Street Zen lowered shares of Eli Lilly and Company from a “buy” rating to a “hold” rating in a report on Saturday. One investment analyst has rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $1,313.43.

Get Our Latest Stock Analysis on Eli Lilly and Company

Insider Activity at Eli Lilly and Company

In related news, CAO Donald Zakrowski sold 2,000 shares of the business’s stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $1,185.01, for a total value of $2,370,020.00. Following the completion of the sale, the chief accounting officer directly owned 1,526 shares of the company’s stock, valued at $1,808,325.26. The trade was a 56.72% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Patrik Jonsson sold 6,500 shares of the company’s stock in a transaction that occurred on Monday, August 17th. The shares were sold at an average price of $1,175.10, for a total value of $7,638,150.00. Following the sale, the executive vice president owned 54,147 shares in the company, valued at $63,628,139.70. The trade was a 10.72% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 13,500 shares of company stock valued at $15,958,170 over the last three months. 0.14% of the stock is owned by insiders.

Key Stories Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

Positive Sentiment: Omvoh delivered positive pediatric trial results. In the Phase 3 SHINE-2 study, 81% of children with moderately to severely active ulcerative colitis achieved a clinical response after induction, while half of responders reached clinical remission after one year. Lilly plans to submit the data to regulators for a potential pediatric label expansion. Lilly Omvoh pediatric ulcerative colitis trial results
Positive Sentiment: Foundayo and the broader GLP-1 franchise remain key growth drivers. European regulators recommended approval of Lilly’s oral weight-loss treatment Foundayo, while analysts expect it to continue gaining market share. Strong GLP-1 sales are also expected to support upcoming third-quarter results. European Union regulators recommend Foundayo approval
Positive Sentiment: Lilly expanded its drug-delivery capabilities. The company signed a collaboration with Metis TechBio valued at up to $1.1 billion, potentially accelerating development of AI-enabled drug-delivery technology. Metis TechBio drug-delivery collaboration
Neutral Sentiment: Lilly will present updates on several oncology candidates at the ESMO Congress, including treatments targeting ovarian, lung, thyroid and breast cancers. The data could broaden the company’s growth base, although the commercial impact remains dependent on clinical and regulatory outcomes. Lilly oncology pipeline ESMO update
Negative Sentiment: Competition, valuation and legal exposure are weighing on sentiment. Investors are monitoring a potential GLP-1 price war with Novo Nordisk and Lilly’s dependence on a concentrated weight-loss portfolio. A Pennsylvania lawsuit also alleges that insulin manufacturers and pharmacy-benefit managers inflated insulin prices, adding regulatory and reputational risk. Eli Lilly insulin pricing lawsuit

Eli Lilly and Company Company Profile

(Free Report)

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for a range of medical conditions. Its major therapeutic areas include diabetes and obesity, oncology, immunology, neuroscience and cardiovascular health.

The company’s portfolio includes Mounjaro and Trulicity for diabetes, Zepbound for chronic weight management, Humalog insulin, Taltz for inflammatory diseases, Verzenio for certain breast cancers and Kisunla for early symptomatic Alzheimer’s disease.